CFSAN seeks industry reps
This article was originally published in The Tan Sheet
Executive SummaryFDA seeks organizations to help select nonvoting industry representatives to serve on the Center for Food Safety and Applied Nutrition's public advisory committees. Those interested should send a curriculum vitae and the name of the committee they are interested in to FDA by Nov. 23, says an Oct. 22 Federal Register notice
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.